MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019
04 nov. 2019 08h30 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced the presentation of several abstracts at the upcoming American Heart Association (AHA)...
MyoKardia to Evaluate Mavacamten as an Alternative to Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Patients
10 sept. 2019 08h44 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), today announced that it will study mavacamten as a therapeutic alternative to septal reduction therapy...
MyoKardia Announces Abstracts Selected for Presentation at the European Society of Cardiology Congress 2019
26 août 2019 08h30 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the presentation of three abstracts at the upcoming European Society of Cardiology (ESC)...
MyoKardia Announces Positive Six-Month Safety and Efficacy Data from PIONEER-OLE Study of Mavacamten for the Treatment of Symptomatic, Obstructive HCM
04 mars 2019 08h02 HE
|
MyoKardia, Inc.
Mavacamten Well Tolerated; Results Show Statistically Significant Elimination of Obstruction and Durable NYHA Class Improvements Statistically Significant Improvement in Several Key Biomarkers...
MyoKardia Appoints William Fairey as Chief Commercial Officer
23 janv. 2019 08h30 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy
26 juin 2018 08h30 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy
10 mai 2018 08h30 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients
02 avr. 2018 08h30 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients
08 mars 2018 16h02 HE
|
MyoKardia, Inc.
Met Primary Endpoint and Key Secondary Endpoints with Statistical Significance Study Results Inform Phase 3 EXPLORER-HCM Dosing; First Patient Planned for Q2 2018 Conference Call Today...